📊 IVEVF Key Takeaways
Is Inventiva S.A. (IVEVF) a Good Investment?
Inventiva S.A. presents an uninvestable profile due to complete absence of fundamental financial data. With zero revenue reported, negative earnings, and no cash flow visibility, the company appears to be in pre-revenue or development stage with insufficient operational metrics to assess viability. The lack of any measurable financial performance makes fundamental analysis impossible and represents extreme execution risk.
Inventiva’s fundamentals remain weak: it is still a clinical-stage biotech with minimal recurring revenue, deep operating losses, and no evidence of self-sustaining profitability. Liquidity improved materially through repeated financings, but growth quality is low because reported revenue is milestone-driven rather than commercial, and the business still depends on external capital while awaiting pivotal trial outcomes.
Why Buy Inventiva S.A. Stock? IVEVF Key Strengths
- Operates in pharmaceutical sector which has growth potential
- Listed on Nasdaq indicating some regulatory compliance
- Biotech companies can generate significant value upon successful drug development
- Cash position was reinforced in 2025, with €122.1 million of cash and €24.6 million of short-term deposits at June 30, 2025, later supported by additional financing
- Revenue improved in 2025 versus the prior-year period due to milestone payments tied to the CTTQ partnership
- Management disclosed cash runway extending into 2026 and later into early 2027 after additional capital raising, reducing near-term liquidity pressure
IVEVF Stock Risks: Inventiva S.A. Investment Risks
- Zero reported revenue indicates no commercial operations or market traction
- Complete absence of all financial metrics prevents fundamental evaluation
- Pharmaceutical development stage companies face extreme R&D risk and capital requirements
- No cash flow data visible - potential liquidity concerns for ongoing operations
- Minimal insider activity suggests limited institutional confidence
- Data quality severely limited with only 1 metric available
- Net losses remain extremely large, including a €175.9 million loss in the first half of 2025 and continued negative operating results
- Balance-sheet quality is weak, with shareholders’ equity still negative at June 30, 2025
- Revenue quality is poor because it is driven by nonrecurring collaboration milestones rather than product sales, leaving the company highly dependent on financing and clinical success
Key Metrics to Watch
- Revenue recognition and path to commercialization of pipeline products
- Cash runway and burn rate relative to available capital
- Clinical trial progress and regulatory milestones for drug candidates
- Operating expenses and efficiency in capital allocation
- Cash position and ability to fund ongoing R&D activities
- Quarterly cash burn and cash runway
- Progression from milestone revenue to sustainable commercial revenue or regulatory approval milestones
Inventiva S.A. (IVEVF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IVEVF Profit Margin, ROE & Profitability Analysis
IVEVF vs Healthcare Sector: How Inventiva S.A. Compares
How Inventiva S.A. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inventiva S.A. Stock Overvalued? IVEVF Valuation Analysis 2026
Based on fundamental analysis, Inventiva S.A. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inventiva S.A. Balance Sheet: IVEVF Debt, Cash & Liquidity
IVEVF Revenue Growth, EPS Growth & YoY Performance
IVEVF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inventiva S.A. (CIK: 0001756594)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IVEVF
What is the AI rating for IVEVF?
Inventiva S.A. (IVEVF) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IVEVF's key strengths?
Claude: Operates in pharmaceutical sector which has growth potential. Listed on Nasdaq indicating some regulatory compliance. ChatGPT: Cash position was reinforced in 2025, with €122.1 million of cash and €24.6 million of short-term deposits at June 30, 2025, later supported by additional financing. Revenue improved in 2025 versus the prior-year period due to milestone payments tied to the CTTQ partnership.
What are the risks of investing in IVEVF?
Claude: Zero reported revenue indicates no commercial operations or market traction. Complete absence of all financial metrics prevents fundamental evaluation. ChatGPT: Net losses remain extremely large, including a €175.9 million loss in the first half of 2025 and continued negative operating results. Balance-sheet quality is weak, with shareholders’ equity still negative at June 30, 2025.
What is IVEVF's revenue and growth?
Inventiva S.A. reported revenue of N/A.
Does IVEVF pay dividends?
Inventiva S.A. does not currently pay dividends.
Where can I find IVEVF SEC filings?
Official SEC filings for Inventiva S.A. (CIK: 0001756594) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IVEVF's EPS?
Inventiva S.A. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IVEVF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inventiva S.A. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IVEVF stock overvalued or undervalued?
Valuation metrics for IVEVF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IVEVF stock in 2026?
Our dual AI analysis gives Inventiva S.A. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IVEVF's free cash flow?
Inventiva S.A.'s operating cash flow is N/A, with capital expenditures of N/A.
How does IVEVF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).